Dementia works by destroying the brain’s ability to send signals between nerve cells. It isn’t a single disease but a group of conditions that damage neurons and the connections between them, progressively eroding memory, thinking, and eventually basic body functions. Over 57 million people worldwide live with some form of dementia, and the underlying biology varies depending on the type. But in every case, the core problem is the same: brain cells lose their ability to communicate, then they die, and the brain physically shrinks.
What Happens Inside Neurons
The most common form of dementia, Alzheimer’s disease, involves two abnormal proteins: amyloid-beta and tau. In a healthy brain, amyloid-beta is produced and cleared without issue. In Alzheimer’s, fragments of this protein clump together into small toxic clusters called oligomers. These oligomers, even before they form the large plaques visible on brain scans, are already doing damage. Dimers, trimers, and larger groupings of amyloid-beta all impair the brain’s ability to strengthen connections between neurons, a process called long-term potentiation that forms the physical basis of memory.
Tau protein normally acts as structural scaffolding inside neurons, stabilizing the tiny transport tubes that shuttle nutrients from one end of the cell to the other. In Alzheimer’s, tau becomes chemically altered (hyperphosphorylated), detaches from those tubes, and clumps into tangled fibers. The transport system collapses, starving the neuron. Like amyloid-beta, tau doesn’t need to form its final tangled state to be harmful. Soluble tau oligomers are acutely toxic and appear before tangles form, even before a person shows any symptoms.
Both proteins converge on a critical target: a molecular switch involved in memory formation. Amyloid-beta oligomers block this switch from activating during the signaling process that encodes new memories. Tau overexpression does the same thing through a different route. The result is a double hit. The brain loses its ability to lay down new memories and simultaneously loses the structural integrity of the cells trying to do so. Both proteins also reduce levels of a key growth factor that keeps neurons healthy and supports the formation of new connections.
How Nerve Signals Break Down
Neurons talk to each other by releasing chemical messengers (neurotransmitters) across tiny gaps called synapses. Dementia disrupts this process in several ways. Amyloid-beta oligomers cause glutamate, the brain’s main excitatory messenger, to accumulate in synaptic gaps. Normally, glutamate fires a signal and gets quickly cleared. In Alzheimer’s, it lingers, overstimulating the receiving neuron. This overstimulation, called excitotoxicity, eventually kills the cell.
Tau compounds the problem by interacting with the same receptors that glutamate activates, further amplifying the toxic overstimulation. Meanwhile, the cholinergic system, which uses a different neurotransmitter called acetylcholine that is essential for attention and memory, deteriorates early in the disease. This cholinergic decline was one of the earliest biological features identified in Alzheimer’s research and remains the basis for several existing medications that temporarily boost acetylcholine levels.
Not All Dementia Starts the Same Way
While Alzheimer’s accounts for the majority of cases, other types of dementia damage the brain through entirely different mechanisms.
Vascular dementia results from disrupted blood flow to the brain. Small vessel disease, blood clots, or chronic reduced blood flow (hypoperfusion) deprive brain tissue of oxygen. This triggers a cascade of oxidative stress, inflammation, and damage to the brain’s white matter, the insulated wiring that connects different regions. White matter lesions show up as bright spots on brain scans and are associated with declining executive function, attention, and memory. The blood-brain barrier, which normally protects neurons from harmful substances in the bloodstream, breaks down in affected areas, allowing further damage. Carrying the APOE-ε4 gene variant worsens these effects.
Lewy body dementia involves abnormal deposits of a protein called alpha-synuclein that disrupts the brain’s chemical messengers. It produces a distinctive combination of symptoms that sets it apart: visual hallucinations, significant fluctuations in alertness and concentration throughout the day, movement problems resembling Parkinson’s disease (muscle rigidity, reduced facial expression, loss of coordination), and severe sleep disturbances including insomnia and excessive daytime sleepiness. Cognitive decline in Lewy body dementia tends to affect attention and visual-spatial abilities more than memory in the early stages, which helps distinguish it from Alzheimer’s.
How the Brain Changes Over Time
Dementia progresses through recognizable stages, though the pace varies widely from person to person. In the preclinical stage, protein deposits and subtle brain changes are already underway, but neither the person nor anyone around them notices anything wrong. This silent phase can last years or even decades.
The next stage brings mild changes in memory and thinking. A person might repeat questions, misplace things more often, or have trouble with complex tasks they used to handle easily. At this point, daily life is still largely manageable.
As the disease advances to moderate stages, the damage becomes harder to compensate for. Recognizing friends and family becomes difficult. Impulsive or uncharacteristic behavior can emerge. Judgment falters. In severe dementia, communication is lost entirely. Eventually, the brain can no longer coordinate basic body functions. Muscles become rigid, reflexes stop responding normally, and a person loses the ability to swallow and control bladder and bowel functions.
New Ways to Detect and Treat It
Diagnosing Alzheimer’s used to require expensive PET brain scans or spinal fluid collection. A blood test measuring a specific form of the tau protein (p-tau217) now shows 82% sensitivity and 86% specificity for detecting the amyloid deposits that define Alzheimer’s, making earlier and cheaper detection far more accessible. It performs similarly well for detecting tau deposits, with 83% sensitivity and 83% specificity.
On the treatment side, a new class of antibody therapies targets amyloid protein directly. Lecanemab binds to the soluble clusters of amyloid-beta before they form plaques. In its 18-month clinical trial, it significantly slowed cognitive decline compared to placebo. Donanemab targets amyloid that has already deposited into plaques and showed even more pronounced results: a 29% to 36% reduction in the rate of clinical progression depending on the level of tau pathology present, with people who had less tau damage benefiting more. These are not cures. They slow decline rather than stop or reverse it, and they work only in early-stage disease.
Risk Factors You Can Actually Change
The 2024 Lancet Commission identified 14 modifiable risk factors that, if addressed collectively, could prevent roughly 45% of dementia cases worldwide. That’s a striking number for a condition many people assume is purely genetic or inevitable with age.
- Hearing loss is the single largest modifiable contributor, likely because it reduces cognitive stimulation and increases social withdrawal.
- Hypertension, obesity, diabetes, and elevated LDL cholesterol all damage blood vessels that supply the brain, contributing to both vascular and Alzheimer’s-type dementia.
- Physical inactivity reduces blood flow to the brain and misses the neuroprotective effects of exercise.
- Smoking and excessive alcohol directly damage neurons and blood vessels.
- Depression and social isolation are linked to accelerated brain aging and reduced cognitive reserve.
- Lower educational attainment in early life and traumatic brain injuries reduce the brain’s resilience to later damage.
- Air pollution exposure triggers chronic brain inflammation.
- Vision loss, newly added to the list, likely works through similar pathways as hearing loss by reducing sensory input and social engagement.
Managing Daily Life With Dementia
Beyond medication, the day-to-day management of dementia relies heavily on environmental and behavioral strategies. One widely used framework, the ABC model, focuses on identifying the specific trigger for a problematic behavior, the behavior itself, and the consequences or responses that improve or worsen it. A more refined version called DICE walks caregivers through describing the behavior in detail (when it happens, who’s involved, where), investigating possible causes (pain, hunger, overstimulation, a medication side effect), creating a targeted plan, and evaluating whether it works.
Practical environmental changes make a real difference. Reducing background noise, simplifying social situations, and minimizing clutter help a person with dementia focus without becoming overwhelmed. Removing access to items that cause problems, like credit cards or car keys, prevents risky situations without confrontation. Addressing sensory needs that the person can no longer communicate, such as being cold, hungry, or in pain, often resolves agitation that otherwise seems to come from nowhere.
Sleep disruption is common, and nighttime restlessness can exhaust both the person with dementia and their caregiver. Increased daytime walking combined with exposure to bright light has been shown to reduce nighttime awakenings. Structured activity programs that match tasks to a person’s remaining abilities also significantly reduce agitation. Caregiver education programs that teach communication strategies, home safety modifications, and stress reduction techniques protect both the person with dementia and the caregiver’s own health.